Login to Your Account

Clinic Roundup

Thursday, June 6, 2013
• NeuroVive Pharmaceutical AB, of Stockholm, Sweden, recruited the first patient in a Phase IIa trial evaluating safety and pharmacokinetics of the company's NeuroSTAT drug candidate in traumatic brain injury. The open-label, uncontrolled study, which is being conducted at Copenhagen (Denmark) University Hospital, expects to enroll 20 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription